BR112015022208A2 - proteínas de fusão que compreendem pdgf e partes de ligação de vegf, seu método de produção bem como seus usos, composição, ácido nucleico, célula hospedeira, vetor, partícula de raav e seu método de produção - Google Patents
proteínas de fusão que compreendem pdgf e partes de ligação de vegf, seu método de produção bem como seus usos, composição, ácido nucleico, célula hospedeira, vetor, partícula de raav e seu método de produçãoInfo
- Publication number
- BR112015022208A2 BR112015022208A2 BR112015022208A BR112015022208A BR112015022208A2 BR 112015022208 A2 BR112015022208 A2 BR 112015022208A2 BR 112015022208 A BR112015022208 A BR 112015022208A BR 112015022208 A BR112015022208 A BR 112015022208A BR 112015022208 A2 BR112015022208 A2 BR 112015022208A2
- Authority
- BR
- Brazil
- Prior art keywords
- production
- fusion proteins
- pdgf
- binding moieties
- well
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title abstract 3
- 101150030763 Vegfa gene Proteins 0.000 title abstract 3
- 239000002245 particle Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 2
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 230000003612 virological effect Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
resumo patente de invenção: "proteínas de fusão que compreende pdgf e partes de ligação de vegf e métodos de utilização do mesmo". a presente invenção refere-se as proteínas de fusão que compreendem as porções de ligação pdgf e vegf, e as partículas virais recombinantes que codificam as proteínas de fusão. as composições que compreendem as proteínas de fusão e as partículas virais, bem como métodos de utilização das mesmas também são fornecidas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780914P | 2013-03-13 | 2013-03-13 | |
PCT/US2014/026872 WO2014160507A1 (en) | 2013-03-13 | 2014-03-13 | Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015022208A2 true BR112015022208A2 (pt) | 2017-10-10 |
BR112015022208A8 BR112015022208A8 (pt) | 2018-01-23 |
Family
ID=50680144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015022208A BR112015022208A8 (pt) | 2013-03-13 | 2014-03-13 | proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo |
Country Status (27)
Country | Link |
---|---|
US (4) | US9637534B2 (pt) |
EP (1) | EP2968461B1 (pt) |
JP (2) | JP6561042B2 (pt) |
KR (1) | KR102228921B1 (pt) |
CN (1) | CN105188733B (pt) |
AR (1) | AR095437A1 (pt) |
AU (2) | AU2014243712B2 (pt) |
BR (1) | BR112015022208A8 (pt) |
CA (1) | CA2904623A1 (pt) |
DK (1) | DK2968461T3 (pt) |
ES (1) | ES2933558T3 (pt) |
FI (1) | FI2968461T3 (pt) |
HK (1) | HK1220618A1 (pt) |
HR (1) | HRP20221447T1 (pt) |
HU (1) | HUE060464T2 (pt) |
IL (2) | IL240950B (pt) |
LT (1) | LT2968461T (pt) |
MX (1) | MX363533B (pt) |
PL (1) | PL2968461T3 (pt) |
PT (1) | PT2968461T (pt) |
RS (1) | RS63820B1 (pt) |
RU (1) | RU2692652C2 (pt) |
SG (3) | SG10201912956YA (pt) |
SI (1) | SI2968461T1 (pt) |
TW (1) | TWI631133B (pt) |
UY (1) | UY35407A (pt) |
WO (1) | WO2014160507A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
KR102228921B1 (ko) | 2013-03-13 | 2021-03-16 | 젠자임 코포레이션 | Pdgf 및 vegf 결합 부분을 포함하는 융합 단백질 및 이의 이용방법 |
US20160137717A1 (en) * | 2013-06-20 | 2016-05-19 | Gabriela Burian | Use of a vegf antagonist in treating choroidal neovascularisation |
EP3041513B1 (en) | 2013-09-08 | 2020-08-05 | Kodiak Sciences Inc. | Factor viii zwitterionic polymer conjugates |
KR101819135B1 (ko) | 2014-03-18 | 2018-01-18 | 한국과학기술원 | 당화 vegf 디코이 수용체 융합 단백질 |
WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CN107208076A (zh) | 2014-10-17 | 2017-09-26 | 科达制药 | 丁酰胆碱酯酶两性离子聚合物缀合物 |
US11299531B2 (en) | 2015-03-11 | 2022-04-12 | Allgenesis Biotherapeutics Inc. | Fusion protein comprising a ligand binding domain of VEGF and PDGF |
JP6655718B2 (ja) * | 2015-06-28 | 2020-02-26 | オールジェネシス バイオセラピューティクス インコーポレイテッド | 血管新生を阻害するための融合タンパク質 |
EP3377101A4 (en) * | 2015-11-19 | 2019-08-07 | Zhuhai Tairuishang Biopharm Ltd. | VEGF BINDING METHODS AND COMPOSITIONS |
KR20180104635A (ko) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
WO2017172853A1 (en) | 2016-03-30 | 2017-10-05 | Ab Biosciences, Inc. | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use |
KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
JP6849390B2 (ja) * | 2016-10-28 | 2021-03-24 | 花王株式会社 | 関節のこわばり改善剤 |
KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
WO2019083171A2 (ko) * | 2017-10-26 | 2019-05-02 | 주식회사 큐로진생명과학 | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물 |
US11548931B2 (en) | 2017-11-16 | 2023-01-10 | Xl-Protein Gmbh | PASylated VEGFR/PDGFR fusion proteins and their use in therapy |
CN111406071B (zh) * | 2017-11-16 | 2024-01-16 | 成都硕德药业有限公司 | Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途 |
US11524053B2 (en) * | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
US20230024569A1 (en) * | 2019-12-04 | 2023-01-26 | Cdmogen Co., Ltd. | Composition for treating diabetic retinopathy, comprising raav containing soluble vegfr-1 variant cdna |
CN111826400A (zh) * | 2020-07-21 | 2020-10-27 | 中科宝承生物医学科技有限公司 | 一种双特异性抗体nk细胞制备方法及其细胞和应用 |
CN112961250B (zh) * | 2021-03-01 | 2023-06-06 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
CN113105558A (zh) * | 2021-04-01 | 2021-07-13 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法 |
EP4355767A1 (en) * | 2021-06-18 | 2024-04-24 | Ikarovec Limited | Retinal disorders |
WO2023199951A1 (ja) * | 2022-04-13 | 2023-10-19 | 株式会社セルージョン | 抗vegf機能を有する多能性幹細胞及びその分化細胞 |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
WO2024029876A1 (ko) * | 2022-08-02 | 2024-02-08 | 주식회사 파노로스바이오사이언스 | 변형된 융합 단백질 및 이의 용도 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4454151A (en) | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US4952515A (en) | 1987-05-22 | 1990-08-28 | Polymer Technology International Corp. | Method of detection using a test strip having a non particulate dialyzed polymer layer |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
AU1411092A (en) | 1991-01-31 | 1992-09-07 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
DE60117550T2 (de) | 2000-06-01 | 2006-12-07 | University Of North Carolina At Chapel Hill | Doppelsträngige parvovirus-vektoren |
US20030181531A1 (en) | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
AU2003218168A1 (en) | 2002-03-15 | 2003-09-29 | University Of Southern California | Ophthalmic solutions for delivery of expression vectors |
US20040058313A1 (en) | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
ES2347340T3 (es) | 2004-09-13 | 2010-10-28 | Genzyme Corporation | Construcciones multimericas. |
US7765583B2 (en) | 2005-02-28 | 2010-07-27 | France Telecom | System and method for managing virtual user domains |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
DE102005020510A1 (de) | 2005-04-29 | 2006-11-09 | Basf Ag | Verbundelement, insbesondere Fensterscheibe |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN101951925A (zh) | 2008-02-20 | 2011-01-19 | 建新公司 | 血管发生抑制 |
EP2604279A1 (en) | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
CN102311502B (zh) * | 2010-07-10 | 2013-12-25 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
AU2011336592A1 (en) * | 2010-12-02 | 2013-07-11 | Neurotech Usa, Inc. | Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof |
CN105949313B (zh) | 2011-03-29 | 2021-06-15 | 罗切格利卡特公司 | 抗体Fc变体 |
CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
KR102228921B1 (ko) | 2013-03-13 | 2021-03-16 | 젠자임 코포레이션 | Pdgf 및 vegf 결합 부분을 포함하는 융합 단백질 및 이의 이용방법 |
-
2014
- 2014-03-13 KR KR1020157027849A patent/KR102228921B1/ko active IP Right Grant
- 2014-03-13 EP EP14722439.8A patent/EP2968461B1/en active Active
- 2014-03-13 MX MX2015011951A patent/MX363533B/es unknown
- 2014-03-13 SG SG10201912956YA patent/SG10201912956YA/en unknown
- 2014-03-13 ES ES14722439T patent/ES2933558T3/es active Active
- 2014-03-13 WO PCT/US2014/026872 patent/WO2014160507A1/en active Application Filing
- 2014-03-13 AR ARP140100983A patent/AR095437A1/es unknown
- 2014-03-13 CA CA2904623A patent/CA2904623A1/en not_active Abandoned
- 2014-03-13 BR BR112015022208A patent/BR112015022208A8/pt not_active IP Right Cessation
- 2014-03-13 LT LTEPPCT/US2014/026872T patent/LT2968461T/lt unknown
- 2014-03-13 SI SI201432005T patent/SI2968461T1/sl unknown
- 2014-03-13 HR HRP20221447TT patent/HRP20221447T1/hr unknown
- 2014-03-13 DK DK14722439.8T patent/DK2968461T3/da active
- 2014-03-13 UY UY0001035407A patent/UY35407A/es not_active Application Discontinuation
- 2014-03-13 HU HUE14722439A patent/HUE060464T2/hu unknown
- 2014-03-13 PT PT147224398T patent/PT2968461T/pt unknown
- 2014-03-13 TW TW103109211A patent/TWI631133B/zh not_active IP Right Cessation
- 2014-03-13 SG SG10201707501TA patent/SG10201707501TA/en unknown
- 2014-03-13 AU AU2014243712A patent/AU2014243712B2/en active Active
- 2014-03-13 FI FIEP14722439.8T patent/FI2968461T3/fi active
- 2014-03-13 US US14/210,354 patent/US9637534B2/en active Active
- 2014-03-13 CN CN201480026585.2A patent/CN105188733B/zh active Active
- 2014-03-13 PL PL14722439.8T patent/PL2968461T3/pl unknown
- 2014-03-13 JP JP2016502268A patent/JP6561042B2/ja active Active
- 2014-03-13 RS RS20221155A patent/RS63820B1/sr unknown
- 2014-03-13 RU RU2015142999A patent/RU2692652C2/ru active
- 2014-03-13 SG SG11201506802SA patent/SG11201506802SA/en unknown
-
2015
- 2015-08-31 IL IL240950A patent/IL240950B/en active IP Right Grant
-
2016
- 2016-07-20 HK HK16108675.7A patent/HK1220618A1/zh unknown
-
2017
- 2017-03-28 US US15/471,725 patent/US10183983B2/en active Active
-
2018
- 2018-11-20 US US16/197,194 patent/US11084864B2/en active Active
- 2018-12-12 AU AU2018278902A patent/AU2018278902A1/en not_active Abandoned
-
2019
- 2019-02-04 JP JP2019017599A patent/JP2019123711A/ja active Pending
- 2019-05-19 IL IL266715A patent/IL266715A/en unknown
-
2021
- 2021-07-02 US US17/367,027 patent/US20220064262A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015022208A2 (pt) | proteínas de fusão que compreendem pdgf e partes de ligação de vegf, seu método de produção bem como seus usos, composição, ácido nucleico, célula hospedeira, vetor, partícula de raav e seu método de produção | |
CY1122800T1 (el) | Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων | |
MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
BR112019004711A2 (pt) | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos | |
CR20150258A (es) | Anticuerpos anti-ceacam5 y usos de éstos | |
PH12015500284A1 (en) | Interleukin-10 fusion proteins and uses thereof | |
AR091024A1 (es) | Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos | |
BR112014019901A8 (pt) | Proteínas de fator viii recombinante | |
EA201491494A1 (ru) | Нацеливание на гликаны хондроитинсульфаты | |
BR112014023415A2 (pt) | moléculas que se ligam a ang2 | |
EA201590488A1 (ru) | Способы модификации клеток-хозяев | |
EA201592022A1 (ru) | Расщепляемый тромбином линкер, содержащий xten, и его применение | |
MX2014004598A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
MX2014004539A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
MX2017009153A (es) | Proteinas de fusion de citoquinas. | |
CL2014003464A1 (es) | Método para mejorar la integridad deteriorada de la unión neuromuscular que comprende la administración de una composición que comprende un vector viral adeno-asociado recombinante (raav) que comprende una molécula de ácido nucleico que codifica la alfa-glucosidasa ácida (gaa). | |
AR092879A1 (es) | Proteinas de fusion de g3p como agentes de union a amiloide | |
MD20150109A2 (ro) | Construcţii proteice mitocondriale şi utilizările acestora | |
BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina | |
BR112014015933A2 (pt) | métodos e materiais para reduzir a degradação das proteínas recombinantes | |
MX2013010392A (es) | Proteinas de fusion npp1. | |
IN2015DN03206A (pt) | ||
UY34662A (es) | Acido nucleico y proteina recombinante del gen de la toxina axmi335, vectores, células, composiciones y métodos para proteger plantas | |
BR112015022464A2 (pt) | anticorpos anti-cd52, seu método de preparação bem como seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, linhagem celular isolada, e composição | |
MY180183A (en) | Methods and compositions for preventing norleucine misincorporation into proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2713 DE 03-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |